Dosing, administration, and safety of radium-223: How I do it.
Publication/Presentation Date
6-1-2016
Abstract
Radium-223 dichloride is a first-in-class bone-directed radiopharmaceutical that has been shown to prolong survival in men with metastatic castrate resistant prostate cancer (mCRPC). Unlike other radiopharmaceuticals, radium-223 uniquely uses alpha-emission to deliver high intensity, short range cytoxic treatments resulting in minimal myelosuppression. Following the results of the ALSYMPCA trial, radium-223 (Xofigo) was FDA approved in the United States in May 2013 and approved by Health Canada in December 2013 for the treatment of mCRPC with symptomatic bone metastases and no visceral disease. This 'How I do it' article describes the background of radium 223 as well as the methods and techniques that our institution uses for safe and effective administration and notes the subtle differences when administering the drug in Canada.
Volume
23
Issue
3
First Page
8301
Last Page
8305
ISSN
1488-5581
Published In/Presented At
Dan, T. D., Doyle, L., Raval, A. J., Pridjian, A., Gomella, L. G., & Den, R. B. (2016). Dosing, administration, and safety of radium-223: How I do it. The Canadian journal of urology, 23(3), 8301–8305.
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
27347625
Department(s)
Administration and Leadership
Document Type
Article